Runxiang Yang
ORCID：0000-0003-3684-5892
发表论文 80 篇 · 总被引 2033 次 · h-index 23
代表论文
- Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer (2025 · Journal of Clinical Oncology · 被引 75)
- Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
- Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
- Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial (2025 · Nature Medicine · 被引 30)
- Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma (2025 · Nature Communications · 被引 16)